• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

具有新型侧链的金刚烷基抗雌激素在抑制乳腺癌细胞中雌激素受体介导的活性方面展现出一系列活性。

Adamantyl Antiestrogens with Novel Side Chains Reveal a Spectrum of Activities in Suppressing Estrogen Receptor Mediated Activities in Breast Cancer Cells.

作者信息

Min Jian, Guillen Valeria Sanabria, Sharma Abhishek, Zhao Yuechao, Ziegler Yvonne, Gong Ping, Mayne Christopher G, Srinivasan Sathish, Kim Sung Hoon, Carlson Kathryn E, Nettles Kendall W, Katzenellenbogen Benita S, Katzenellenbogen John A

机构信息

Department of Cancer Biology, The Scripps Research Institute , Jupiter, Florida 33458, United States.

出版信息

J Med Chem. 2017 Jul 27;60(14):6321-6336. doi: 10.1021/acs.jmedchem.7b00585. Epub 2017 Jul 14.

DOI:10.1021/acs.jmedchem.7b00585
PMID:28657320
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6039301/
Abstract

To search for new antiestrogens more effective in treating breast cancers, we explored alternatives to the acrylic acid side chain used in many antiestrogens. To facilitate our search, we used a simple adamantyl ligand core that by avoiding stereochemical issues enabled rapid synthesis of acrylate ketone, ester, and amide analogs. All compounds were high affinity estrogen receptor α (ERα) ligands but displayed a range of efficacies and potencies as antiproliferative and ERα-downregulating agents. There were large differences in activity between compounds having minor structural changes, but antiproliferative and ERα-downregulating efficacies generally paralleled one another. Some compounds with side chain polar groups had particularly high affinities. The secondary carboxamides had the best cellular activities, and the 3-hydroxypropylamide was as efficacious as fulvestrant in suppressing cell proliferation and gene expression. This study has produced structurally novel antiestrogens based on a simple adamantyl core structure with acrylate side chains optimized for cellular antagonist activity.

摘要

为了寻找在治疗乳腺癌方面更有效的新型抗雌激素药物,我们探索了许多抗雌激素药物中使用的丙烯酸侧链的替代物。为便于研究,我们使用了一个简单的金刚烷基配体核心,通过避免立体化学问题,能够快速合成丙烯酸酯酮、酯和酰胺类似物。所有化合物都是高亲和力雌激素受体α(ERα)配体,但作为抗增殖剂和ERα下调剂,它们表现出一系列的效力和效能。结构上有微小变化的化合物之间活性存在很大差异,但抗增殖和ERα下调效能通常相互平行。一些带有侧链极性基团的化合物具有特别高的亲和力。仲羧酰胺具有最佳的细胞活性,3-羟丙基酰胺在抑制细胞增殖和基因表达方面与氟维司群一样有效。本研究基于一个简单的金刚烷基核心结构,产生了结构新颖的抗雌激素药物,其丙烯酸酯侧链针对细胞拮抗剂活性进行了优化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4909/6039301/f1b0e2cef4f0/nihms978763f11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4909/6039301/82be69d7399d/nihms978763f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4909/6039301/6a551fd14eb2/nihms978763f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4909/6039301/72d9f1007fb9/nihms978763f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4909/6039301/f9fa4c57e788/nihms978763f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4909/6039301/cfbb8c4f35c6/nihms978763f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4909/6039301/a64f92bc90c4/nihms978763f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4909/6039301/9533c73c108f/nihms978763f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4909/6039301/c9f90636b429/nihms978763f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4909/6039301/2d197733ca6e/nihms978763f9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4909/6039301/62d49b7cd66e/nihms978763f10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4909/6039301/f1b0e2cef4f0/nihms978763f11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4909/6039301/82be69d7399d/nihms978763f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4909/6039301/6a551fd14eb2/nihms978763f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4909/6039301/72d9f1007fb9/nihms978763f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4909/6039301/f9fa4c57e788/nihms978763f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4909/6039301/cfbb8c4f35c6/nihms978763f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4909/6039301/a64f92bc90c4/nihms978763f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4909/6039301/9533c73c108f/nihms978763f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4909/6039301/c9f90636b429/nihms978763f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4909/6039301/2d197733ca6e/nihms978763f9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4909/6039301/62d49b7cd66e/nihms978763f10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4909/6039301/f1b0e2cef4f0/nihms978763f11.jpg

相似文献

1
Adamantyl Antiestrogens with Novel Side Chains Reveal a Spectrum of Activities in Suppressing Estrogen Receptor Mediated Activities in Breast Cancer Cells.具有新型侧链的金刚烷基抗雌激素在抑制乳腺癌细胞中雌激素受体介导的活性方面展现出一系列活性。
J Med Chem. 2017 Jul 27;60(14):6321-6336. doi: 10.1021/acs.jmedchem.7b00585. Epub 2017 Jul 14.
2
Novel hybrid conjugates with dual estrogen receptor α degradation and histone deacetylase inhibitory activities for breast cancer therapy.新型杂合体具有双重雌激素受体α降解和组蛋白去乙酰化酶抑制活性,可用于乳腺癌治疗。
Bioorg Med Chem. 2021 Jun 15;40:116185. doi: 10.1016/j.bmc.2021.116185. Epub 2021 May 1.
3
Antiestrogenically active 2-benzyl-1,1-diarylbut-2-enes: synthesis, structure-activity relationships and molecular modeling study for flexible estrogen receptor antagonists.具有抗雌激素活性的2-苄基-1,1-二芳基丁-2-烯:柔性雌激素受体拮抗剂的合成、构效关系及分子模拟研究
Med Chem. 2006 Mar;2(2):147-68. doi: 10.2174/157340606776056142.
4
An adamantyl-substituted retinoid-derived molecule that inhibits cancer cell growth and angiogenesis by inducing apoptosis and binds to small heterodimer partner nuclear receptor: effects of modifying its carboxylate group on apoptosis, proliferation, and protein-tyrosine phosphatase activity.一种金刚烷基取代的类视黄醇衍生分子,通过诱导凋亡抑制癌细胞生长和血管生成,并与小异二聚体伴侣核受体结合:修饰其羧基对凋亡、增殖和蛋白酪氨酸磷酸酶活性的影响。
J Med Chem. 2007 May 31;50(11):2622-39. doi: 10.1021/jm0613323. Epub 2007 May 10.
5
Design and Synthesis of Novel Breast Cancer Therapeutic Drug Candidates Based upon the Hydrophobic Feedback Approach of Antiestrogens.基于抗雌激素的疏水反馈作用设计和合成新型乳腺癌治疗药物候选物。
Molecules. 2019 Nov 1;24(21):3966. doi: 10.3390/molecules24213966.
6
Ethyl side-chain modifications in novel flexible antiestrogens--design, synthesis and biological efficacy in assay against the MCF-7 breast tumor cell line.新型柔性抗雌激素药物中乙基侧链修饰——针对MCF-7乳腺癌细胞系的设计、合成及生物学活性测定
Anticancer Drug Des. 2001 Feb;16(1):57-69.
7
Synthesis and biological evaluation of stilbene-based pure estrogen antagonists.基于芪的纯雌激素拮抗剂的合成与生物学评价
Bioorg Med Chem Lett. 2004 Sep 20;14(18):4659-63. doi: 10.1016/j.bmcl.2004.06.098.
8
Human estrogen receptor α antagonists, part 2: Synthesis driven by rational design, in vitro antiproliferative, and in vivo anticancer evaluation of innovative coumarin-related antiestrogens as breast cancer suppressants.人雌激素受体α拮抗剂,第2部分:基于合理设计的合成、新型香豆素类抗雌激素作为乳腺癌抑制剂的体外抗增殖及体内抗癌评估
Eur J Med Chem. 2022 Jan 5;227:113869. doi: 10.1016/j.ejmech.2021.113869. Epub 2021 Sep 29.
9
Guide-lines in the design of new antiestrogens and cytotoxic-linked estrogens for the treatment of breast cancer.用于治疗乳腺癌的新型抗雌激素和细胞毒性连接雌激素设计指南。
J Steroid Biochem. 1983 Jul;19(1A):75-85.
10
Antitumor and anticancer stem cell activities of eribulin mesylate and antiestrogens in breast cancer cells.甲磺酸艾瑞布林和抗雌激素在乳腺癌细胞中的抗肿瘤及抗癌干细胞活性
Breast Cancer. 2016 May;23(3):425-36. doi: 10.1007/s12282-014-0580-9. Epub 2015 Jan 1.

引用本文的文献

1
Decoding estrogen receptor and GPER biology: structural insights and therapeutic advances in ERα-positive breast cancer.解析雌激素受体和G蛋白偶联雌激素受体生物学:雌激素受体α阳性乳腺癌的结构见解与治疗进展
Front Oncol. 2025 Jun 26;15:1513225. doi: 10.3389/fonc.2025.1513225. eCollection 2025.
2
New generation estrogen receptor-targeted agents in breast cancer: present situation and future prospectives.乳腺癌新一代雌激素受体靶向药物:现状与未来展望
Acta Mater Med. 2024 Feb 21;3(1):57-71. doi: 10.15212/amm-2024-0006. Epub 2024 Mar 15.
3
Heterodimeric GW7604 Derivatives: Modification of the Pharmacological Profile by Additional Interactions at the Coactivator Binding Site.

本文引用的文献

1
Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer.针对难治性乳腺癌研发的新型选择性雌激素受体下调剂(SERDs)
J Med Chem. 2017 Feb 23;60(4):1325-1342. doi: 10.1021/acs.jmedchem.6b01355. Epub 2017 Feb 10.
2
Full antagonism of the estrogen receptor without a prototypical ligand side chain.没有典型配体侧链的雌激素受体的完全拮抗作用。
Nat Chem Biol. 2017 Jan;13(1):111-118. doi: 10.1038/nchembio.2236. Epub 2016 Nov 21.
3
Endocrine treatment in breast cancer: Cure, resistance and beyond.
异二聚体 GW7604 衍生物:通过在共激活剂结合位点的附加相互作用修饰药理学特性。
J Med Chem. 2021 May 13;64(9):5766-5786. doi: 10.1021/acs.jmedchem.0c02230. Epub 2021 Apr 27.
4
Probing the Effect of Halogen Substituents (Br, Cl, and F) on the Non-covalent Interactions in 1-(Adamantan-1-yl)-3-arylthiourea Derivatives: A Theoretical Study.探究卤素取代基(溴、氯和氟)对1-(金刚烷-1-基)-3-芳基硫脲衍生物中非共价相互作用的影响:一项理论研究。
ACS Omega. 2021 Feb 10;6(7):4816-4830. doi: 10.1021/acsomega.0c05793. eCollection 2021 Feb 23.
5
Recent progress in selective estrogen receptor downregulators (SERDs) for the treatment of breast cancer.用于治疗乳腺癌的选择性雌激素受体下调剂(SERDs)的最新进展。
RSC Med Chem. 2020 Mar 6;11(4):438-454. doi: 10.1039/c9md00570f. eCollection 2020 Apr 1.
6
Suppression of breast cancer metastasis and extension of survival by a new antiestrogen in a preclinical model driven by mutant estrogen receptors.新型抗雌激素在突变雌激素受体驱动的临床前模型中抑制乳腺癌转移和延长生存时间。
Breast Cancer Res Treat. 2020 Jun;181(2):297-307. doi: 10.1007/s10549-020-05629-y. Epub 2020 Apr 10.
7
Synthesis and crystal structure of 3-(adamantan-1-yl)-4-(2-bromo-4-fluoro-phen-yl)-1-1,2,4-triazole-5(4)-thione.3-(金刚烷-1-基)-4-(2-溴-4-氟苯基)-1,2,4-三唑-5(4H)-硫酮的合成与晶体结构
Acta Crystallogr E Crystallogr Commun. 2020 Jan 10;76(Pt 2):162-166. doi: 10.1107/S2056989020000092. eCollection 2020 Feb 1.
8
Antagonists for Constitutively Active Mutant Estrogen Receptors: Insights into the Roles of Antiestrogen-Core and Side-Chain.组成型激活的雌激素受体拮抗剂:抗雌激素核心和侧链作用的深入了解。
ACS Chem Biol. 2018 Dec 21;13(12):3374-3384. doi: 10.1021/acschembio.8b00877. Epub 2018 Nov 26.
9
New Class of Selective Estrogen Receptor Degraders (SERDs): Expanding the Toolbox of PROTAC Degrons.新型选择性雌激素受体降解剂(SERD):拓展PROTAC降解结构域的工具库。
ACS Med Chem Lett. 2018 Jul 5;9(8):803-808. doi: 10.1021/acsmedchemlett.8b00106. eCollection 2018 Aug 9.
10
Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance.雌激素受体突变在内分泌治疗耐药中的结构基础。
Nat Rev Cancer. 2018 Jun;18(6):377-388. doi: 10.1038/s41568-018-0001-z.
乳腺癌的内分泌治疗:治愈、耐药及其他。
Cancer Treat Rev. 2016 Nov;50:68-81. doi: 10.1016/j.ctrv.2016.08.008. Epub 2016 Sep 7.
4
Estrogen receptor-α and aryl hydrocarbon receptor involvement in the actions of botanical estrogens in target cells.雌激素受体-α和芳烃受体参与植物雌激素在靶细胞中的作用。
Mol Cell Endocrinol. 2016 Dec 5;437:190-200. doi: 10.1016/j.mce.2016.08.025. Epub 2016 Aug 16.
5
Fulvestrant-3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD).氟维司群-3硼酸(ZB716):一种口服生物可利用的选择性雌激素受体下调剂(SERD)。
J Med Chem. 2016 Sep 8;59(17):8134-40. doi: 10.1021/acs.jmedchem.6b00753. Epub 2016 Aug 29.
6
The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer.选择性雌激素受体下调剂GDC-0810在多种雌激素受体阳性乳腺癌模型中有效。
Elife. 2016 Jul 13;5:e15828. doi: 10.7554/eLife.15828.
7
AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.AZD9496:一种口服雌激素受体抑制剂,可阻断临床前模型中 ER 阳性和 ESR1 突变型乳腺癌肿瘤的生长。
Cancer Res. 2016 Jun 1;76(11):3307-18. doi: 10.1158/0008-5472.CAN-15-2357. Epub 2016 Mar 28.
8
Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation.雌激素受体α体细胞突变Y537S和D538G通过稳定激活功能-2结合构象赋予乳腺癌内分泌抗性。
Elife. 2016 Feb 2;5:e12792. doi: 10.7554/eLife.12792.
9
Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer.用于抗他莫昔芬乳腺癌的选择性人雌激素受体部分激动剂(ShERPAs)
J Med Chem. 2016 Jan 14;59(1):219-237. doi: 10.1021/acs.jmedchem.5b01276. Epub 2015 Dec 30.
10
Multiple Beneficial Roles of Repressor of Estrogen Receptor Activity (REA) in Suppressing the Progression of Endometriosis.雌激素受体活性抑制因子(REA)在抑制子宫内膜异位症进展中的多种有益作用
Endocrinology. 2016 Feb;157(2):900-12. doi: 10.1210/en.2015-1324. Epub 2015 Dec 14.